Labcorp Holdings Inc Dossier
|
SectorHealth Care IndustryDiagnostics & Research Beta (adjusted)0.92 Intrinsic Value $272.66median of 6 methods · middle span $218-$301based on filings through 30 Jun 2026 Market Price $304.60Price as of 1 Oct 2026 Near fair valueIntrinsic value is 10% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $24.7B Enterprise Value $30.4B Shares Outstanding 82.1M diluted Moat Rating Narrow Next Earnings Date22 Oct 2026 Last ex-dividend28 Aug 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Labcorp entered the second half of 2026 with healthy operating momentum: second-quarter revenue increased 5.8%, adjusted EPS increased 14.9%, and adjusted operating margin expanded 70 basis points. Diagnostics and Biopharma Laboratory Services both grew revenue and expanded margins, while management raised full-year revenue and adjusted-EPS guidance. The constructive operating outlook is balanced by modest Diagnostics organic volume growth, a Biopharma book-to-bill ratio only slightly above 1.0, lower first-half free cash flow, elevated debt, and execution demands from acquisitions and increased capital investment. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$270.00 Mean target$337.75 High · most bullish analyst$385.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $280.0020% Diagnostics organic volume stalls, payer or reimbursement pressure limits price/mix, Biopharma book-to-bill falls below 1.0, and slower backlog conversion combines with acquisition and capital-spending demands. Adjusted EPS falls below the updated guidance floor and weaker cash conversion reduces capital-return flexibility. Base CaseCentral scenario $337.7555% Matches the consensus meanLabcorp delivers within its updated 2026 revenue range of $14.710 billion to $14.827 billion and adjusted-EPS range of $18.10 to $18.55. Diagnostics produces positive organic volume and price/mix, Central Labs offsets weaker Early Development activity, and margins retain most recent efficiency gains. Bull CaseUpside scenario $390.0025% Specialty-testing launches, health-system partnerships, Central Labs demand and operating efficiencies sustain above-guidance growth. Biopharma book-to-bill remains above 1.0, backlog converts as expected, margins continue expanding, and the enlarged repurchase authorization supports per-share growth. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |